WHO GRADE 3 GLIOMA
Clinical trials for WHO GRADE 3 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new WHO GRADE 3 GLIOMA trials appear
Sign up with your email to follow new studies for WHO GRADE 3 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young brain cancer patients: targeted pill combo after radiation shows promise
Disease control OngoingThis study tests whether taking two targeted pills (dabrafenib and trametinib) after radiation therapy can help children and young adults up to age 25 with a specific type of aggressive brain cancer (BRAF V600-mutant high-grade glioma). The drugs block proteins that fuel tumor gr…
Matched conditions: WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:32 UTC
-
New hope for rare cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…
Matched conditions: WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:21 UTC
-
Brain cancer radiation showdown: which therapy saves your smarts?
Symptom relief OngoingThis study compares proton beam therapy to standard photon radiation (IMRT) in 120 people with IDH-mutant grade II or III gliomas. The goal is to see which method better preserves memory and thinking skills after treatment. Both techniques aim to deliver radiation precisely to th…
Matched conditions: WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 26, 2026 04:38 UTC